Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: Long-term efficacy and safety outcomes

Annals of Oncology

Volumn 24, Issue 11, 2013, Pages 2887-2892

  Necchi, A ^a   Nicolai, N ^a   Mariani, L ^a   Raggi, D ^a   Fare E ^a   Giannatempo, P ^a   Catanzaro, M ^a   Biasoni, D ^a   Torelli, T ^a   Stagni, S ^a   Milani, A ^a   Piva, L ^a   Pizzocaro, G ^b   Gianni, A M ^a,c   Salvioni, R ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b San Giuseppe Hospital   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Combination chemotherapy; Salvage therapies; Testicular neoplasms

Indexed keywords

CISPLATIN; ETOPOSIDE; IFOSFAMIDE;

ADULT; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEBRILE NEUTROPENIA; FOLLOW UP; GASTROINTESTINAL TOXICITY; GERM CELL TUMOR; HIGH RISK PATIENT; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; THROMBOCYTOPENIA;

COMBINATION CHEMOTHERAPY; SALVAGE THERAPIES; TESTICULAR NEOPLASMS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ETOPOSIDE; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; PROGNOSIS; REMISSION INDUCTION; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 84887044918     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt271     Document Type: Article

References (18)

1. Feldman DR, Bosl GJ, Sheinfeld J et al. Medical treatment of advanced testicular cancer. JAMA 2008; 299: 672-684.
2. Loehrer PJ, Einhorn LH, Williams SD. VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer. J Clin Oncol 1986; 4: 528-536.
3. Harstrick A, Schmoll HJ, Wilke H et al. Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma. J Clin Oncol 1991; 9: 1549-1555.
4. Loehrer PJ, Gonin R, Nichols CR et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 1998; 7: 2500-2504.
5. Motzer RJ, Cooper K, Geller NL et al. The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors. Cancer 1990; 66: 2476-2481.
6. Farhat F, Culine S, Theodore C et al. Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients. Cancer 1996; 77: 1193-1197.
7. McCaffrey JA, Mazumdar M, Bajorin DF et al. Ifosfamide and cisplatin-containing chemotherapy as forst-salvage therapy in germ cell tumors: response and survival. J Clin Oncol 1997; 15: 2559-2563.
8. Kondagunta GV, Bacik J, Donadio A et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 2005; 23: 6549-6555.
9. Pizzocaro G, Salvioni R, Piva L et al. Modified cisplatin, etoposide (or vinblastine) and ifosfamide salvage therapy for male germ-cell tumors. Long-term results. Ann Oncol 1992; 3: 211-216.
10. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events, version 4.03. NIH. http://ctep.cancer.gov/protocolDevelopment/ electronic_applications/ctc.htm#ctc_40 (Accessed 20 June 2012).
11. The International prognostic factors study group. Lorch A, Beyer J, Bascoul-Mollevi C et al. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol 2010; 28: 4906-4911.
12. Motzer RJ, Geller NL, Tan CC et al. Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan Kettering Cancer Center experience (1979-1989). Cancer 1991; 67: 1305-1310.
13. International Germ Cell Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15: 594-603.
14. Pico JL, Rosti G, Kramar A et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy from advanced germ cell tumours. Ann Oncol 2005; 16: 1152-1159.
15. Mead GM, Cullen MH, Huddart R et al. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. Br J Cancer 2005; 93: 178-184.
16. Einhorn LH, Williams SD, Chamness A et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 2007; 26: 340-348.
17. Feldman DR, Sheinfeld J, Bajorin DF et al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol 2010; 28: 1706-1713.
18. Lorch A, Bascoul-Mollevi C, Kramar A et al. Conventional-dose versus high-dose chemotherapy as first-salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol 2011; 29: 2178-2184.